Tonix Pharmaceuticals Holding (TNXP) EBIAT (2023 - 2025)
Historic EBIAT for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$31.8 million.
- Tonix Pharmaceuticals Holding's EBIAT fell 10102.29% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.7 million, marking a year-over-year increase of 3109.61%. This contributed to the annual value of -$136.7 million for FY2024, which is 1718.1% down from last year.
- Latest data reveals that Tonix Pharmaceuticals Holding reported EBIAT of -$31.8 million as of Q3 2025, which was down 10102.29% from -$27.4 million recorded in Q2 2025.
- Tonix Pharmaceuticals Holding's EBIAT's 5-year high stood at -$15.8 million during Q3 2024, with a 5-year trough of -$77.3 million in Q2 2024.
- Its 3-year average for EBIAT is -$29.7 million, with a median of -$27.3 million in 2023.
- Over the last 5 years, Tonix Pharmaceuticals Holding's EBIAT had its largest YoY gain of 6462.14% in 2025, and its largest YoY loss of 10102.29% in 2025.
- Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's EBIAT stood at -$27.3 million in 2023, then grew by 17.72% to -$22.5 million in 2024, then crashed by 41.62% to -$31.8 million in 2025.
- Its last three reported values are -$31.8 million in Q3 2025, -$27.4 million for Q2 2025, and -$16.1 million during Q1 2025.